Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Glycanage D O O maintains 1 pending office action in the Biotechnology & Pharmaceuticals sector. Prosecution is concentrated under 1 distinct examiner and 1 distinct art unit. This indicates a highly specialized or early-stage portfolio where all current legal efforts are focused on a single technological hurdle. The Biotechnology & Pharmaceuticals area often involves complex examination, and here it is limited to a single point of contact.
OGUNTADE, ELIZABETH BISOLA is the busiest examiner, managing the pending office action for the company. With only a single examiner involved, the company's immediate patent prospects are tied to the evaluation of this specific individual. The use of a single art unit suggests that the subject matter is contained within a specific sub-discipline of biotechnology. Practitioners should focus on the specific patterns of OGUNTADE, ELIZABETH BISOLA to navigate this matter successfully.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OGUNTADE, ELIZABETH BISOLA | 1 | 50.0% | +100.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18373311 | METHOD FOR THE ASSESSMENT OF PERIMENOPAUSE OR MENOPAUSE STATUS VIA ANALYSIS OF THE IgG GLYCOME | OGUNTADE, ELIZABETH BISOLA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18373311 | METHOD FOR THE ASSESSMENT OF PERIMENOPAUSE OR MENOPAUSE STATUS VIA ANALYSIS OF THE IgG GLYCOME | OGUNTADE, ELIZABETH BISOLA | — |
| Art Unit | Apps |
|---|---|
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18373311 | METHOD FOR THE ASSESSMENT OF PERIMENOPAUSE OR MENOPAUSE STATUS VIA ANALYSIS OF THE IgG GLYCOME | OGUNTADE, ELIZABETH BISOLA | 1677 | §101§103§112DP | Final Rejection | — | Pending | Sep 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGlycanage D O O has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Elizabeth Bisola Oguntade has the most, with 1 of Glycanage D O O's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
